AI Stock Memo: STE - STERIS - RankAlpha

STE

Rating buyAI Memo

STERIS

As of 2026-02-05/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-05 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

high

Horizon

—

Key catalyst

Large hospital procurement / contract renewals window • 2026-09-30

Expected move: +29%

Biggest risk

Procurement delays, reimbursement pressure, or execution miscues on integration could compress margins and slow service revenue growth, leaving shares below current levels until visibility returns.

Invalidation

Break below $230 or thesis failure.

What would change my mind?

Execution of integration and sustained service-annuity growth drives margin expansion; analyst high targets and favorable procurement cycles lift shares toward or above the analyst high as hospitals renew multi-year service contracts.

Research note

Recommendation

buy

Confidence

high

As of

2026-02-05

Base target

$274

p=60%

Bull target

$300

p=25%

Bear target

$230

p=15%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly earnings (conservative estimate)
Integration-driven margin expansion and product adoption
Execution of integration and sustained service-annuity growth drives margin expansion; analyst high targets and favorable procurement cycles lift shares toward or above the analyst high as hospitals renew multi-year service contracts.

BearKey bullets

Large-hospital procurement delays
Regulatory or reimbursement shifts reducing utilization
Supply-chain or integration execution failures

WatchKey bullets

Large hospital procurement / contract renewals window

Summary

High-level snapshot

Recommendation

buy

Model confidence

high

Timeframe

Asset

Equity

Trigger

Base case: $274 (p=60%)

Bull/Bear spread: +41% / +8%

Vs latest close: Bull +41% · Base +29% · Bear +8%

Scenario probabilities

Bull Target: $300 (p=25%)Base Target: $274 (p=60%)Bear Target: $230 (p=15%)

Commentary

Analyst coverage is constructive: the median 12-month target ($274.35) sits above today's price, implying a base-case upside and further upside toward the analyst high if execution and contract timing hold [#SERP-2][#SERP-9]. Near-term re-rating will track quarterly guidance and any large-system contract announcements; execution or procurement delays are the primary triggers for downside [#SERP-4].

As of 2026-02-05 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Procurement delays, reimbursement pressure, or execution miscues on integration could compress margins and slow service revenue growth, leaving shares below current levels until visibility returns.

Drivers

Scannable catalysts and supporting factors

Next quarterly earnings (conservative estimate)
Integration-driven margin expansion and product adoption

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-05Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$274.35

Range (USD)

$250.00 - $300.00

Count

Query: STERIS plc Common (STE) analyst consensus price target high low average

STERIS (STE) Stock Forecast & Price Target - Investing.com
Search result #1
According to projections from 8 analysts, the average 12-month price target for STERIS is 281.63, with a high estimate of 300 and a low estimate of 231.
Open source
STERIS (STE) Stock Forecast and Price Target 2026 - MarketBeat
Search result #2
According to the 8 analysts' twelve-month price targets for STERIS, the average price target is $275.20. The highest price target for STE is $295.00, while the ...
Extracted: $275.20, $295.00Open source
STERIS plc: Target Price Consensus and Analysts Recommendations
Search result #3
STERIS plc analysts consensus, targets, ratings and recommendations | Nyse: STE | Nyse. ... Evolution of the Average Target: STERIS plc. Evolution of the Target ...
Open source
STERIS plc (STE) Stock Price, News, Quote & History - Yahoo Finance
Search result #4
News headlines Steris (STE) reported solid Q3 earnings with $1.5 billion in revenue and an EPS of $2.53, meeting analyst expectations.
Extracted: $1.50, $2.53Open source
What is the current Price Target and Forecast for STERIS (STE)
Search result #5
The forecasts range from a low of $256.00 to a high of $300.00. The average price target represents an increase of 9.32% from the last closing price of $264.24.
Extracted: $256.00, $300.00, $264.24Open source
STERIS plc Stock Price: Quote, Forecast, Splits & News (STE)
Search result #6
Analysts maintain a "Moderate Buy" consensus with an average price target of $273.50, implying further upside from current levels, as the company continues to ...
Extracted: $273.50Open source

Scenarios

Bull Target (Scenario probability)

$300 / p=25% prob

Base Target (Scenario probability)

$274 / p=60% prob

Bear Target (Scenario probability)

$230 / p=15% prob

Price $213 as of 2026-05-27

Nearest Scenario: Bear (∆ 8%)

Targets vs latest close: Bull +41% · Base +29% · Bear +8%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
Large hospital procurement / contract renewals window
Major procurement cycles and multi-year hospital contract renewals can materially shift sterilization and instrument-service revenues; no single public date disclosed, assumed window end for planning purposes (assumption: end of procurement window) [#SERP-1].
Prob 40.00% • Move 8.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Next quarterly earnings (conservative estimate)
2026-05-06
Upcoming quarterly report may drive short-term re-rating around organic growth and margins; prior quarter reported ~$1.5 billion revenue and EPS $2.53, which sets expectations for continuity or downside risk [#SERP-4]. Date is estimated per short-horizon rule.
Prob 65% • Move 6% • Priced-in 45%

Long-term Catalysts

Months to a year

Integration-driven margin expansion and product adoption
2027-02-05
Medium–long term gains from acquisition integration, cross-selling sterilization and surgical portfolio, and service-annuity growth should materialize over the next year; analyst consensus targets imply upside if execution holds [#SERP-2][#SERP-9].
Prob 55% • Move 25% • Priced-in 50%

Risks

Large-hospital procurement delays
Regulatory or reimbursement shifts reducing utilization
Supply-chain or integration execution failures

Peers

Symbol	Summary
TMO	Thermo Fisher Scientific — large diversified life‑sciences and lab equipment franchise; comparable exposure to lab consumables and instrument sales.
DHR	Danaher Corporation — medical technologies and diagnostics with recurring revenue models and service agreements similar to STERIS.
BAX	Baxter International — hospital products and supply relationships that overlap with STERIS end markets and purchasing dynamics.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: STERIS plc Common (STE) analyst consensus price target high low average
Analysis date: 2026-02-05